Medivation
CureTech reclaims rare disease drug from Pfizer for $20 million
October 2, 2017Sales and Marketing Clal Biotechnology, CureTech, Medivation, Pfizer, pharma, pharmaceutical
CureTech, a biotech firm owned by Clal Biotechnology Industries, is set to reclaim a drug it sold more than two …
Pfizer acquires Medivation for $14 billion
August 22, 2016Sales and Marketing Medivation, Pfizer, acquisition, oncology
Pfizer has sealed the deal to acquire US cancer drug company Medivation for close to $14 billion in a move …
MSD joins Medivation race, says reports
August 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
Earnings drop at Sanofi as it looks for a quick Medivation resolution
July 29, 2016Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings
Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …
AstraZeneca mulling a $10-billion bid for Medivation – report
July 12, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition
Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …
Weekly Movers: Medivation, Bind Therapeutics, Insys…
July 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing Medivation, XBiotech, juno therapeutics, markets, stocks
Medivation (Nasdaq: MDVN) stock rose after the company announced it has entered a confidentiality agreement with a number of parties …
Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal
July 6, 2016Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer
Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …
Sanofi to add future payments onto Medivation offer, according to reports
June 23, 2016Research and Development, Sales and Marketing Medivation, Sanofi
Sanofi (NYSE: SNY) is considering adding future payments, tied to certain targets, to its proposed $9.3 billion takeover of US …
Sanofi looks to set date for showdown with Medivation shareholders
June 2, 2016Sales and Marketing Medivation, Sanofi, hostile, record date, shareholders, takeover
Sanofi (NYSE: SNY) has announced that it has attempted to fix a record date with Medivation (NASDAQ: MDVN) where the …
Sanofi makes move to remove Medivation board; Medivation hits back
May 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Medivation, Sanofi, removal of board, takeover
Sanofi (NYSE: SNY) has taken their proposed takeover of Medivation (NASDAQ: MDVN) up several notches, with the French company filing …
Sanofi to replace entire Medivation board to drive sale, according to reports
May 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing Medivation, Sanofi, replace board, takeover
Reports have emerged that Sanofi is looking to step up its efforts to take over oncology firm, Medivation, as it …
Sanofi Files Hart-Scott-Rodino notification for Medivation acquisition
May 13, 2016Medical Communications, Sales and Marketing M&A, MA, Medivation, Sanofi, deal
French drugmaker Sanofi (Euronext: SAN) on Friday said it has filed a premerger notification with the US Department of Justice Antitrust …
Medivation maybe mulling sale as bidding race heats up – Reports
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …
Focus: Medivation tug-of-war rumbles on
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war
Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
